北交所策略专题报告 2026 年 03 月 01 日 AI+医疗渗透提升项自主智能体升级，掘金北交所 AI 诊疗标的 北交所研究团队 ——北交所策略专题报告 诸海滨（分析师） 车欣航（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 chexinhang@kysec.cn 政策赋能+技术迭代双重驱动，AI+医疗渗透提升向自主智能体方向持续升级 随着生成式大模型等 AI 技术的迭代，AI+医疗已全面渗透医疗产业各环节。AI 医疗是依托机器学习、自然语言处理、计算机视觉等技术，深度分析复杂医疗数 据，辅助临床决策、优化诊疗流程、提升医疗效率的智能化应用体系，核心价值 在于提升医疗服务质量、增强可及性并降低成本。政策层面形成完善顶层设计， 2025 年 10 月五部门联合发布相关实施意见，明确 2027 年建成高质量医疗数据 集与专病垂直大模型、广泛应用基层诊疗智能辅助等目标，2030 年实现基层 AI 辅助全覆盖、二级以上医院普遍应用 AI 影像与临床决策辅助，并确定八大应用 重点方向。同年 12 月，相关专项行动将 AI 药物研发等列为重点支持领域；2026 年 1 月，国 ...

北交所策略专题报告 2026 年 03 月 01 日 AI+医疗渗透提升项自主智能体升级，掘金北交所 AI 诊疗标的 北交所研究团队 ——北交所策略专题报告 诸海滨（分析师） 车欣航（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 chexinhang@kysec.cn 政策赋能+技术迭代双重驱动，AI+医疗渗透提升向自主智能体方向持续升级 随着生成式大模型等 AI 技术的迭代，AI+医疗已全面渗透医疗产业各环节。AI 医疗是依托机器学习、自然语言处理、计算机视觉等技术，深度分析复杂医疗数 据，辅助临床决策、优化诊疗流程、提升医疗效率的智能化应用体系，核心价值 在于提升医疗服务质量、增强可及性并降低成本。政策层面形成完善顶层设计， 2025 年 10 月五部门联合发布相关实施意见，明确 2027 年建成高质量医疗数据 集与专病垂直大模型、广泛应用基层诊疗智能辅助等目标，2030 年实现基层 AI 辅助全覆盖、二级以上医院普遍应用 AI 影像与临床决策辅助，并确定八大应用 重点方向。同年 12 月，相关专项行动将 AI 药物研发等列为重点支持领域；2026 年 1 月，国 ...

（文章来源：证券日报） 证券日报网讯 2月26日，森萱医药发布2025年年度业绩快报公告称，公司2025年实现营业收入 552577290.50元，同比增长2.87%；归属于上市公司股东的净利润131575798.33元，同比增长6.32%。 ...

证券代码：920946 证券简称：森萱医药 公告编号：2026-004 江苏森萱医药股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 552,577,290.50 | 537,136,066.43 | 2.87% | | 利润总额 | 159,045,522.15 | 147,211,649.23 | 8.04% | | 归属于上市公司股东的净利润 | 131,575,798.33 | 123,759,884.41 | 6.32% | | 归属于上市公司股东的扣除非 | 127,969,849.80 | 116,722 ...

Industry Overview - In 2025, the Chinese chemical industry is experiencing a complex situation of cyclical bottoming and structural optimization, with significant internal differentiation [2] - Traditional basic chemicals are seeing slowed growth and prominent supply-demand structural contradictions, while specific sub-sectors are maintaining strong growth, becoming new engines for industry development [2] High-Profit Sectors Analysis - The pharmaceutical sector, particularly in chemical preparations, has an average profit margin exceeding 22%, driven by rigid demand, aging population, and high entry barriers [6][7] - The raw materials segment also maintains a profit margin around 22%, with companies like Hai Sheng Pharmaceutical and Senxuan Pharmaceutical expected to exceed 30% in annual profit margins [6][7] - The rubber deep processing sector, benefiting from the rapid development of the new energy vehicle industry, has an average profit margin of about 22%, with companies like Litong Technology and Kelong New Materials showing average profitability above 24% [8][9] - The oil and gas sector, with an average profit margin of 22%, is experiencing profit improvements due to the gradual relaxation of oil exploration and extraction permissions by the government [10] Low-Profit Sectors Analysis - The gas sector, with an average profit margin below 3%, faces challenges from price volatility and regulatory constraints, limiting its growth potential [11] - The traditional chemical products sector also struggles with an average profit margin below 3%, impacted by overcapacity and weak demand [12][13] - The petrochemical trade sector, similarly, has an average profit margin below 3%, reflecting deep-seated contradictions of overcapacity and declining demand for refined oil products [13] - The chemical fiber sector is facing profitability issues due to low demand in textiles and oversupply of conventional fibers [13] Industry Insights - The chemical industry is highly influenced by macroeconomic factors, with demand being the core variable determining product prosperity [14] - Key trends for 2025 include a shift towards high-value-added segments, the rise of the new energy industry reshaping demand structures, and the release of policy dividends in oil and gas sectors [14] - Companies like Bluestar Technology demonstrate that differentiation and technological upgrades can provide pathways for success in overcapacity industries [14]

Group 1 - The core point of the article highlights that the North Exchange 50 index has experienced a decline of 1.12% over the past 50 days [2] - Among the constituent stocks, Naconor has seen a drop of 4.32%, while Senxuan Pharmaceutical has decreased by 3.93% [2] - Other notable declines include Yinuowei with a decrease of 3.51% and Tianma New Materials falling by 3.15% [2]

江苏森萱医药股份有限公司 | | 计划减 | 计划减持 | | | | 拟减 | 拟减 | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 持数量 | 数量占总 | 减持 | 减持 | 减持价 | 持股 | 持 | | 称 | （股） | 股本比例 | 方式 | 期间 | 格区间 | 份来 | 原因 | | | | （%） | | | | 源 | | | 姜春娟 | 18,750 | 0.004392% | 集中 | 公告披露之 | 根据市 | 北交 | 个人 | | | | | 竞价 | 日起 15 个交 | 场交易 | 所上 | 资金 | | | | | | 易日后的 3 个 | 价格确 | 市前 | 需求 | | | | | | 月内 | 定 | 取得 | | 二、 本次减持计划的主要内容 （一） 单个主体拟在 3 个月内集中竞价方式减持股份总数是否超过公司股份总 数 1% □是 √否 证券代码：920946 证券简称：森萱医药 公告编号：2026-003 江苏森萱医药股份有限公司 股东拟减持股份的预披露公告 本公司及董事会全体成员及相 ...

为出具本法律意见书，本所律师对本次股东会所涉及的有关事项进行了审 查，查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 森萱医药 2026 年第一次临时股东会法律意见书 江苏世纪同仁律师事务所 关于江苏森萱医药股份有限公司 2026 年第一次临时股东会的法律意见书 江苏森萱医药股份有限公司： 根据《公司法》《证券法》和中国证监会《上市公司股东会规则》等法律、 法规和规范性文件以及《公司章程》的规定，本所受贵公司董事会的委托，指派 本所律师出席贵公司 2026 年第一次临时股东会，并就本次股东会的召集、召开 程序、出席会议人员资格、召集人资格、表决程序和表决结果的合法有效性出具 法律意见。 本所律师同意将本法律意见书随贵公司本次股东会决议一并公告，并依法对 本法律意见书承担相应的责任。 本所律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的业 务标准、道德规范和勤勉尽责精神，出具法律意见如下： 一、关于本次股东会的召集、召开程序 1、本次股东会由贵公司董事会召集。 贵公司第四届董事会第十二次会议决定于 2026 年 1 月 15 日召开本次股东 会。贵公司已于 2025 年 12 月 30 日 ...

一、会议召开和出席情况 江苏森萱医药股份有限公司 证券代码：920946 证券简称：森萱医药 公告编号：2026-001 江苏森萱医药股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 （一）会议召开情况 1.会议召开时间：2026 年 1 月 15 日 2.会议召开地点：江苏省南通市崇川区青年中路 198 号国城广场 A 幢 21 楼 会议室 3.会议召开方式：现场投票和网络投票相结合 4.会议召集人：董事会 5.会议主持人：吴玉祥 6.召开情况合法合规的说明： 本次股东会的召集、召开、议案审议符合《公司法》等有关法律、法规及《公 司章程》的规定。 （二）会议出席情况 出席和授权出席本次股东会的股东共 6 人，持有表决权的股份总数 321,777,930 股，占公司有表决权股份总数的 75.372244%。 其中通过网络投票参与本次股东会的股东共 2 人，持有表决权的股份总数 12,878,490 股，占公司有表决权股份总数的 3.016617%。 1. ...

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]